NCT05822245View on ClinicalTrials.gov

A Study of PER-001 in Participants With Open-Angle Glaucoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 25, 2023

Primary Completion Date

April 4, 2025

Study Completion Date

April 4, 2026

Conditions
Open-angle Glaucoma
Interventions
DRUG

PER-001 Intravitreal Implant - Low Dose

PER-001 Low Dose Intravitreal Implant

DRUG

PER-001 Intravitreal Implant - High Dose

PER-001 High Dose Intravitreal Implant

DRUG

PER-001 Intravitreal Implant - Sham

PER-001 Intravitreal Sham

Trial Locations (1)

94158

Perfuse Therapeutics, Inc., San Francisco

Sponsors
All Listed Sponsors
lead

Perfuse Therapeutics, Inc.

INDUSTRY

NCT05822245 - A Study of PER-001 in Participants With Open-Angle Glaucoma | Biotech Hunter | Biotech Hunter